China’s Healthcare Reforms A Great Start But Institutional Weakness Could Hamper Progress – The Lancet
This article was originally published in PharmAsia News
Executive Summary
China’s biggest weakness is institutional, which makes it difficult for its large and growing healthcare system to be effective, say report authors.
You may also be interested in...
With A/H1N1, A Spectre Is Haunting China: The Spectre Of SARS
BEIJING - As China's government mulls whether to galvanize a dozen vaccine producers across the country to turn out up to 300 million doses of an A/H1N1 defense and continues with the rapid-fire quarantine of anyone suspected of having contact with swine flu victims, health authorities are meeting with World Health Organization representatives to coordinate closely Beijing's response to the pandemic
Southeast Asian Regulators Ramp Up Anti-Corruption, Bribery Enforcement Ahead of ASEAN Pact
Regulators in Southeast Asia are working to tighten bribery and corruption enforcement as part of a broader push ahead of an Association of Southeast Asian Nations trade pact in 2015 for greater transparency in pharmaceuticals.
St. Jude Introduces Allure Quadra To Hong Kong As It Seeks APAC Rebound For Pacemakers
The first commercial implant for St. Jude’s Allure Quadra in Hong Kong is a sign for optimism for its pacemaker business after last year’s disappointments in Japan.